The impact of psoriasis on pregnancy outcomes.
Lima, Xinaida T, Vanitha Janakiraman, Michael D Hughes, and Alexandra B Kimball. 2012. “The Impact of Psoriasis on Pregnancy Outcomes.”. The Journal of Investigative Dermatology 132 (1): 85-91.
Search
Search results
717 results found
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball, Alexa B, Arielle G Bensimon, Annie Guérin, Andrew P Yu, Eric Q Wu, Martin M Okun, Yanjun Bao, Shiraz R Gupta, and Parvez M Mulani. 2011. “Efficacy and Safety of Adalimumab Among Patients With Moderate to Severe Psoriasis With Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.”. American Journal of Clinical Dermatology 12 (1): 51-62.
Economic burden of comorbidities in patients with psoriasis is substantial.
Kimball, A B, A Guérin, M Tsaneva, A P Yu, E Q Wu, S R Gupta, Y Bao, and P M Mulani. 2011. “Economic Burden of Comorbidities in Patients With Psoriasis Is Substantial.”. Journal of the European Academy of Dermatology and Venereology : JEADV 25 (2): 157-63.
A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis.
Alora-Palli, Maria B, Irina Brouda, Barbara Green, and Alexandra B Kimball. 2010. “A Cost-Effectiveness Comparison of Liquor Carbonis Distillate Solution and Calcipotriol Cream in the Treatment of Moderate Chronic Plaque Psoriasis.”. Archives of Dermatology 146 (8): 919-22.
Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis.
Lima, Hermenio Cavalcante, and Alexandra Boer Kimball. 2010. “Targeting IL-23: Insights into the Pathogenesis and the Treatment of Psoriasis.”. Indian Journal of Dermatology 55 (2): 171-5.
Psoriasis and the life cycle of persistent life effects.
Garshick, Marisa Kardos, and Alexa Boer Kimball. 2015. “Psoriasis and the Life Cycle of Persistent Life Effects.”. Dermatologic Clinics 33 (1): 25-39.
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).
Kimball, A B, C Leonardi, M Stahle, W Gulliver, M Chevrier, S Fakharzadeh, K Goyal, et al. 2014. “Demography, Baseline Disease Characteristics and Treatment History of Patients With Psoriasis Enrolled in a Multicentre, Prospective, Disease-Based Registry (PSOLAR).”. The British Journal of Dermatology 171 (1): 137-47.
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
Mattei, P L, K C Corey, and A B Kimball. 2014. “Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The Correlation Between Disease Severity and Psychological Burden in Patients Treated With Biological Therapies.”. Journal of the European Academy of Dermatology and Venereology : JEADV 28 (3): 333-7.
Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
Kimball, A B, J Schenfeld, N A Accortt, M S Anthony, K J Rothman, and D Pariser. 2014. “Incidence Rates of Malignancies and Hospitalized Infectious Events in Patients With Psoriasis With or Without Treatment and a General Population in the U.S.A.: 2005-09.”. The British Journal of Dermatology 170 (2): 366-73.
Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants.
Lima, X T, R Minnillo, J M Spencer, and A B Kimball. 2013. “Psoriasis Prevalence Among the 2009 AAD National Melanoma/Skin Cancer Screening Program Participants.”. Journal of the European Academy of Dermatology and Venereology : JEADV 27 (6): 680-5.